BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 22429330)

  • 1. Relevance of PTEN loss in brain metastasis formation in breast cancer patients.
    Wikman H; Lamszus K; Detels N; Uslar L; Wrage M; Benner C; Hohensee I; Ylstra B; Eylmann K; Zapatka M; Sauter G; Kemming D; Glatzel M; Müller V; Westphal M; Pantel K
    Breast Cancer Res; 2012 Mar; 14(2):R49. PubMed ID: 22429330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases.
    Hohensee I; Lamszus K; Riethdorf S; Meyer-Staeckling S; Glatzel M; Matschke J; Witzel I; Westphal M; Brandt B; Müller V; Pantel K; Wikman H
    Am J Pathol; 2013 Jul; 183(1):83-95. PubMed ID: 23665199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical relevance of loss of 11p15 in primary and metastatic breast cancer: association with loss of PRKCDBP expression in brain metastases.
    Wikman H; Sielaff-Frimpong B; Kropidlowski J; Witzel I; Milde-Langosch K; Sauter G; Westphal M; Lamszus K; Pantel K
    PLoS One; 2012; 7(10):e47537. PubMed ID: 23118876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatic mutations of the PTEN/NMAC1 gene associated with frequent chromosomal loss detected using comparative genomic hybridization in endometrial cancer.
    Hirai Y; Tanaka N; Furuta R; Kawaguchi T; Sakamoto M; Shirahama S; Noda T
    Gynecol Oncol; 2001 Oct; 83(1):81-8. PubMed ID: 11585417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.
    Gonzalez-Angulo AM; Ferrer-Lozano J; Stemke-Hale K; Sahin A; Liu S; Barrera JA; Burgues O; Lluch AM; Chen H; Hortobagyi GN; Mills GB; Meric-Bernstam F
    Mol Cancer Ther; 2011 Jun; 10(6):1093-101. PubMed ID: 21490305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases.
    Priedigkeit N; Hartmaier RJ; Chen Y; Vareslija D; Basudan A; Watters RJ; Thomas R; Leone JP; Lucas PC; Bhargava R; Hamilton RL; Chmielecki J; Puhalla SL; Davidson NE; Oesterreich S; Brufsky AM; Young L; Lee AV
    JAMA Oncol; 2017 May; 3(5):666-671. PubMed ID: 27926948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role for loss of nuclear PTEN in a harbinger of brain metastases.
    Nosaka R; Yamasaki F; Saito T; Takayasu T; Kolakshyapati M; Amatya VJ; Takeshima Y; Sugiyama K; Kurisu K
    J Clin Neurosci; 2017 Oct; 44():148-154. PubMed ID: 28688620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer.
    Da Silva L; Simpson PT; Smart CE; Cocciardi S; Waddell N; Lane A; Morrison BJ; Vargas AC; Healey S; Beesley J; Pakkiri P; Parry S; Kurniawan N; Reid L; Keith P; Faria P; Pereira E; Skalova A; Bilous M; Balleine RL; Do H; Dobrovic A; Fox S; Franco M; Reynolds B; Khanna KK; Cummings M; Chenevix-Trench G; Lakhani SR
    Breast Cancer Res; 2010; 12(4):R46. PubMed ID: 20604919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer.
    Staaf J; Jönsson G; Ringnér M; Baldetorp B; Borg A
    Breast Cancer Res; 2011; 13(6):R129. PubMed ID: 22169037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTEN mediates the cross talk between breast and glial cells in brain metastases leading to rapid disease progression.
    Hohensee I; Chuang HN; Grottke A; Werner S; Schulte A; Horn S; Lamszus K; Bartkowiak K; Witzel I; Westphal M; Matschke J; Glatzel M; Jücker M; Pukrop T; Pantel K; Wikman H
    Oncotarget; 2017 Jan; 8(4):6155-6168. PubMed ID: 28008153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort.
    Pollack IF; Hamilton RL; James CD; Finkelstein SD; Burnham J; Yates AJ; Holmes EJ; Zhou T; Finlay JL;
    J Neurosurg; 2006 Nov; 105(5 Suppl):418-24. PubMed ID: 17328268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic alterations of the tumor suppressor gene PTEN/MMAC1 in human brain metastases.
    Hahn M; Wieland I; Koufaki ON; Görgens H; Sobottka SB; Schackert G; Schackert HK
    Clin Cancer Res; 1999 Sep; 5(9):2431-7. PubMed ID: 10499615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas.
    Yadav AK; Renfrow JJ; Scholtens DM; Xie H; Duran GE; Bredel C; Vogel H; Chandler JP; Chakravarti A; Robe PA; Das S; Scheck AC; Kessler JA; Soares MB; Sikic BI; Harsh GR; Bredel M
    JAMA; 2009 Jul; 302(3):276-89. PubMed ID: 19602687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q.
    Boström J; Cobbers JM; Wolter M; Tabatabai G; Weber RG; Lichter P; Collins VP; Reifenberger G
    Cancer Res; 1998 Jan; 58(1):29-33. PubMed ID: 9426052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.
    Nuciforo PG; Aura C; Holmes E; Prudkin L; Jimenez J; Martinez P; Ameels H; de la Peña L; Ellis C; Eidtmann H; Piccart-Gebhart MJ; Scaltriti M; Baselga J
    Ann Oncol; 2015 Jul; 26(7):1494-500. PubMed ID: 25851628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy.
    Press RH; Zhang C; Cassidy RJ; Ferris MJ; Zhong J; Steuer CE; Pillai RN; Owonikoko TK; Kahn S; Ramalingam SS; Patel PR; Curran WJ; Shu HG; Sica GL; Higgins KA
    Cancer; 2018 Sep; 124(17):3586-3595. PubMed ID: 30120912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accumulation of genetic alterations in brain metastases of sporadic breast carcinomas is associated with reduced survival after metastasis.
    Hampl M; Hampl JA; Schwarz P; Frank S; Hahn M; Schackert G; Saeger HD; Schackert HK
    Invasion Metastasis; 1998-1999; 18(2):81-95. PubMed ID: 10364688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of EGFR and PTEN numerical aberrations in the evaluation of diffusely infiltrating astrocytomas. Laboratory investigation.
    Mott RT; Turner KC; Bigner DD; McLendon RE
    J Neurosurg; 2008 Feb; 108(2):330-5. PubMed ID: 18240930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer.
    Ach T; Zeitler K; Schwarz-Furlan S; Baader K; Agaimy A; Rohrmeier C; Zenk J; Gosau M; Reichert TE; Brockhoff G; Ettl T
    Virchows Arch; 2013 Jan; 462(1):65-72. PubMed ID: 23242174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor suppressor PTEN in breast cancer: heterozygosity, mutations and protein expression.
    Kechagioglou P; Papi RM; Provatopoulou X; Kalogera E; Papadimitriou E; Grigoropoulos P; Nonni A; Zografos G; Kyriakidis DA; Gounaris A
    Anticancer Res; 2014 Mar; 34(3):1387-400. PubMed ID: 24596386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.